Would you recommend complement testing in a kidney transplant recipient with chronic antibody-mediated rejection and biopsy-proven thrombotic microangiopathy to determine the need for eculizumab?
Answer from: at Community Practice
There is basic and translational data to support the role of IL-6 in acute and chronic humoral rejection, with small single-center trials investigating the use of agents that blockade IL-6/IL-6 receptor interactions for humoral rejection in kidney transplantation. In many of these studies, there is ...
Comments
at Washington University in St. Louis That's very helpful, thank you Dr. @Lee.
at University Of Alabama Birmingham Nephrology I agree with Dr. @Lee that tocilizumab holds promi...
at Washington University in St. Louis Got it Dr. @Ong. Thank you!
That's very helpful, thank you Dr. @Lee.
I agree with Dr. @Lee that tocilizumab holds promi...
Got it Dr. @Ong. Thank you!